New hope for saving failing kidney transplants

NCT ID NCT07006532

Recruiting now Disease control Sponsor: Shahid Beheshti University of Medical Sciences Source: ClinicalTrials.gov ↗

Summary

This study is testing whether adding a drug called tocilizumab to standard treatments helps kidney transplant recipients whose bodies are slowly rejecting their new kidneys. Researchers will compare two treatment combinations in 50 participants to see which better preserves kidney function. The goal is to find more effective ways to help transplants last longer when current treatments aren't working well enough.

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for KIDNEY TRANSPLANT REJECTION are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Contacts and locations

Show contact details

Study contacts

Contact

Phone: •••-•••-•••• Email: •••••@•••••
Contact

Locations

Nooshin Dalili
RECRUITING

Tehran, 1666663421, Iran

Contact Phone: •••-•••-•••• Email: •••••@•••••

Conditions

Explore the condition pages connected to this study.

KIDNEY TRANSPLANT REJECTION